Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 NOTA AE105 - Curasight

Next Previous
Drug Profile

Gallium-68 NOTA AE105 - Curasight

Alternative Names: 68Ga-NOTA-AE105; 68Ga-NOTA-Asp-Cha-Phe-Ser-Arg-Tyr-Leu-Trp-Ser; CS 001; uTRACE; uTREAT

Latest Information Update: 02 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curasight
  • Developer Curasight; Rigshospitalet
  • Class Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Glioblastoma; Gynaecological cancer; Head and neck cancer; Mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Oropharyngeal cancer; Prostate cancer

Most Recent Events

  • 26 Aug 2025 EMA approves the clinical trial application for Gallium-68 NOTA AE105 (uTREAT) in Cancer (Diagnosis)
  • 26 Aug 2025 Curasight plans a phase I trial for Cancer (Diagnosis) in Europe (IV) by the end of 2025
  • 13 Feb 2024 Curasight plans a phase I/II basket trial for Glioblastoma, Neuroendocrine tumors, Head and neck cancer, Non-small cell lung cancer and pancreatic cancer(Diagnosis)(IV) in the beginning of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top